About Fosun Wanbang Pharma Group

Fosun Wanbang Group is accelerating its innovation process and making all effort to shape its innovative competitiveness in focused fields. The company continuously strengthens its advantages in relying on complex formulation technology platforms including inhalation/nasal spray and long-acting injection, recombinant protein/insulin Escherichia coli fermentation platform, and multi-peptide/nucleic acid multi-technology platform, providing solid technical support for the research and development of innovative drugs. The dedicatedR&D team has strong professional capabilities and high comprehensive qualities, with the proportion of high-level talents such as master's and doctoral degrees reaching 56%. It has also set up R&D laboratories in many places such as Shanghai, Suzhou and Xuzhou. On average, it applies for over fifty national patents each year, and several new products are launched annually. In the past five years, a total of seven innovative drugs and biosimilars have been approved for launch, and five products have received marketing approval from the US FDA.

Fosun Wanbang Group is capable of flexible intelligent manufacturing, green production and full-process visual control from raw materials to preparations. It has a strong production capacity for multiple dosage forms, covering small volume injections, tablets, hard capsules, ointments, creams, inhalation preparations, and therapeutic biological products, etc. The company actively promotes the alignment of its quality system with that of leading international enterprises, achieving remarkable results in international certification: The sterile injection production line located at the production site at Yangshan Road in Xuzhou, has passed on-site inspections by the EU EMA and the US FDA, and the oral solid dosage form workshop has also passed on-site inspections by the US FDA. The soft cream workshop located at the production site in Baoshan, Shanghai, has passed the PICs certification. A total of three member enterprise laboratories within the group have passed the CNAS certification.

Fosun Wanbang Group possesses a strong professional medical promotion capability. Focusing on patients and end users, it centers on patients and is driven by scientific and technological innovation to build a full-channel, ecological commercial platform. It continuously provides high-quality innovative drugs, treatment plans, and drug guarantee systems, and actively collaborates with academic societies and top experts to jointly promote the dissemination of cutting-edge diagnosis and treatment concepts, assist in improving the level of clinical diagnosis and treatment. With a professional team of over 4,000 people, through the close collaboration of sales, marketing, medicine, admission, distribution, retail, e-commerce and various functional departments, we achieve comprehensive business penetration and efficient operation. In 2024, the business will cover over 8,000 grade hospitals and more than 400,000 retail pharmacies. Eighteen products ranked No.1 in market sales volume within the same category (IQVIA data), and the sales revenue of 23 products exceeded 100 million yuan.

The company actively fulfills its corporate social responsibility, vigorously promotes the construction of the EHS system, and continuously increases its public welfare investment. Public welfare projects such as the "Bang Plan", "Wanbang Diabetic Care Home", "Wanbang Scholarship", "Hand-in-Hand Rural Medical Talent Revitalization Plan", "Famous Doctors' Lectures", and "Famous Doctors Going to the Countryside" have been making continuous efforts in medical assistance, education support, and community care, enjoying a good social reputation.